Companies / Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc.
Nasdaq: ACRSCIK 1557746WAYNE, PA
Financials · FY2025
Ownership
147.2M shares outstanding · as of Jul 31, 2026
Ownership
| Insiders | 1.40% | 2,056,794 |
| 10%+ / strategic | 30.06% | 44,245,629 |
| Institutions | 57.81% | 85,095,328 |
| Public float | 10.73% | 15,801,142 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 10
View all →| Insider | % of shares | Shares |
|---|---|---|
Leonard Braden Michael10% owner | 9.48% | 13,950,000 |
Walker NealCEOCEO · Director | 1.05% | 1,543,886 |
Loerop JamesChief Business Officer | 0.13% | 192,260 |
Balthaser KevinChief Financial Officer | 0.13% | 187,453 |
Davis Hugh M.President and COO · Director | 0.03% | 45,425 |
Gowen MaxineDirector | 0.02% | 33,334 |
Milano VincentDirector | 0.02% | 28,896 |
Schiff Andrew NDirector | 0.02% | 25,540 |
Hall Jesse WayneChief Medical Officer | — | — |
Kolbeck Roland WilhelmChief Scientific Officer | — | — |
Institutional holders 126
View all →| Holder | Value | % of shares |
|---|---|---|
| $63.35M | 8.14% | |
| $53.10M | 6.82% | |
| $26.76M | 6.04% | |
| $25.52M | 4.62% | |
| $19.57M | 4.42% | |
| $17.22M | 2.21% | |
| $14.52M | 2.63% | |
| $13.41M | 3.03% | |
| $12.60M | 2.28% | |
| $12.17M | 2.75% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | RA Capital Management, L.P. 13F manager | New | Common stock | $25.52M | +6.8M | 6,804,072 4.62% of shares | medium |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $17.10M | +3.2M +47.50% | 10,037,008 6.82% of shares | medium |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | New | Common stock | $12.60M | +3.4M | 3,361,328 2.28% of shares | medium |
| Q2 2026 as of | BML Capital Management, LLC 13F manager | Trim | Common stock | $-12.03M | -2.3M -15.96% | 11,975,000 8.14% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common stock | $9.25M | +1.7M +116.10% | 3,255,340 2.21% of shares | medium |
| Q1 2026 as of | D. E. Shaw & Co., Inc. 13F manager | Trim | Common stock | $-4.48M | -1.2M -57.04% | 900,804 0.61% of shares | low |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | Trim | Common stock | $-2.34M | -623K -55.33% | 502,631 0.34% of shares | low |
| Q1 2026 as of | Adage Capital Partners Gp, L.L.C. 13F manager | Add | Common stock | $1.88M | +500K +14.83% | 3,871,000 2.63% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| BML Investment Partners, L.P. | Passive13G/A | — |
| Biosion, Inc. | Passive13G/A | — |
| BlackRock, Inc. | Passive13G/A | — |
| Deep Track Capital, LP | Passive13G | — |
| RA Capital Management, L.P. | Passive13G | — |
| BML Investment Partners, L.P. | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| ACRS | — | 00461U105 |